Biovica Collaborates with Tempus to Expand the Commercial Reach of DiviTum(R) TKa
UPPSALA, SE / / May 13, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, has entered a reference lab agreement with Tempus, a leader in AI and data-driven precision medicine. Tempus will offer Biovica's blood-based treatment monitoring test, DiviTum TKa, as part of its comprehensive portfolio of diagnostics for oncologists.
Through the collaboration, Biovica and Tempus will work together to commercialize Biovica's FDA-approved DiviTum TKa test, a blood-based test that monitors and predicts treatment response in hormone receptor-positive metastatic breast cancer. Tempus currently works with over 6,500 oncologists in the U.S., providing a collection of precision medicine solutions designed to support physicians in delivering personalized patient care. The collaboration significantly expands Biovica's market reach, leveraging Tempus' established sales network.
" We are excited to work with Biovica to bring DiviTum TKa to breast cancer patients. The treatment landscape in estrogen receptor-positive breast cancer has improved dramatically in the last 5 years with the introduction of HER2-targeted agents, a new generation of endocrine inhibitors, and the expansion of CDK4/6i into the adjuvant setting," said Ezra Cohen, MD, Chief Medical Officer, Oncology, at Tempus.
" Tempus represents the future of healthcare by enabling data-driven precision medicine using AI. This collaboration significantly enhances our ability to deliver DiviTum TKa to a broader patient population. We are confident that our work together will significantly accelerate uptake for DiviTum TKa in the important community oncologist segment of the US market, " said Anders Rylander, CEO of Biovica.
Contact
Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: anders.rylander@biovica.com
Anders Morén, CFOPhone: +46 73 125 92 46E-mail: anders.moren@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: www.biovica.com
Attachments
Biovica collaborates with Tempus to expand the commercial reach of DiviTum® TKa
SOURCE: Biovica International
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
10 minutes ago
- Medscape
Upadacitinib Outperforms Mycophenolate in SSc-ILD Treatment
BARCELONA, Spain — The JAK inhibitor upadacitinib can effectively treat systemic sclerosis-associated interstitial lung disease (SSc-ILD), according to results from a new clinical trial. Patients treated with upadacitinib had reduced rates of decline in forced vital capacity (FVC) at 24 weeks of treatment compared to those treated with mycophenolate mofetil. After 1 year, the difference in the annual rate of decline between the two groups was 20.9 mL/y, favoring upadacitinib ( P = .05). 'We can conclude that upadacitinib was an effective treatment for interstitial lung disease,' said first author Manal Hassanien, MD, PhD, of Assiut University in Asyut, Egypt. She presented the clinical findings at European Alliance of Associations for Rheumatology (EULAR) 2025 Annual Meeting. 'It has a beneficial effect in reducing the rate of decline in FVC in patients with SSc-ILD, [with] some beneficial response in the skin of the diffuse type of systemic sclerosis, and an acceptable safety profile.' Upadacitinib is currently approved by the FDA for the treatment of rheumatoid arthritis, adult and juvenile psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, atopic dermatitis, Crohn's disease, and ulcerative colitis. Currently, nintedanib and tocilizumab are the only FDA-approved treatments for SSc-ILD. Commenting on the study for Medscape Medical News , Iulia Szabo, MD, PhD, a rheumatologist at 'Iuliu Hațieganu' University of Medicine and Pharmacy, Cluj-Napoca, Romania, said the results were 'really promising.' Previous systematic reviews of the literature have also found encouraging evidence using other JAK inhibitors, such as tofacitinib, in SSc-ILD treatment, although the data were mostly in vitro or experimental, Szabo said. She moderated the session where the abstract was presented. 'In a field where we have so little options at our disposal, this [study] is very interesting,' she said. Study Details In the double-blinded, randomized study, researchers enrolled 57 patients with SSc with disease onset of more than 3 years. Of these patients, 57% had the diffuse cutaneous type of SSc. All patients had an FVC < 75% of the predicted normal value, a diffusing capacity of the lungs for carbon monoxide (DLCO) < 80% of the predicted normal value, and at least 10% fibrosis scarring in a high-resolution CT scan. Patients were aged on average about 33 years, and 80% were women. Patients were randomly assigned in a 1:1 ratio to receive a daily dose of 15 mg upadacitinib or 2000 mg mycophenolate. Researchers assessed FVC decline at 12, 24, and 52 weeks, as well as DLCO and changes in the modified Rodnan skin score (mRSS). At 52 weeks, 20.6% of the upadacitinib group and 37.5% of the mycophenolate group had ≥ 5% absolute decline from baseline in FVC. A 10% drop in FVC from baseline at 1 year was also more common in patients taking mycophenolate (17.9%) than in those taking upadacitinib (6.8%). The change in DLCO (as a percentage of the predicted value) at 52 weeks was -62.7 mL in the upadacitinib group and -93.3 mL in the mycophenolate group. The change from baseline in mRSS in patients with the diffuse type of SSc was numerically different between the two groups after 1 year, but this difference was not statistically significant. No significant adverse events were detected in either group. Because the age of the participants in this study trended younger, there may be a higher risk for these events as patients age, Szabo noted. 'The problem we might have will be with older patients because we know all the adverse effects that JAK inhibitors have, and probably we should be a bit more cautious,' she said.
Bloomberg
36 minutes ago
- Bloomberg
Balderton Capital's Liautaud on Europe Investment, AI
Balderton Capital Managing Partner Bernard Liautaud speaks to Bloomberg's Tom Mackenzie on the sidelines of the Founders Forum in Oxfordshire. He says that Europe's goal isn't to out scale other regions in AI, but the aim is to build an ecosystem to achieve compute, data, talent, and regulatory support. This interview occurred on Thursday June 12. (Source: Bloomberg)
Wall Street Journal
39 minutes ago
- Wall Street Journal
Europe's Exporters Feel the Chill From Trump Tariffs
Europe's exports dropped sharply in April as demand was squeezed by President Trump's tariff increases, leading to a fall in factory output that suggests economic growth has slowed after a strong start to the year. European Union exports fell by close to 10% compared with a month earlier, a dramatic reversal from the increase in March as American importers stocked up ahead of Trump's tariff announcement.
